This pattern continues until you reach your maintenance dose, where most patients experience minimal to no nausea within 6 to 12 weeks
Developed by Eli Lilly, this medication is in a new class of weight loss treatments emerging alongside well-known options, such as semaglutide (Wegovy) and tirzepatide (Mounjaro)
Meanwhile, Chinese companies are rapidly advancing through fast following, innovation and licensing, with key developments including Innovents mazdutide, Innogens supaglutide, Hengruis oral candidate HRS-7535, United Laboratories licensing of its first-in-class triple-G (GLP-1, gastric inhibitory polypeptide (GIP) and glucagon) a gonist to Novo Nordisk and Ascletis positive Phase 1 results for its oral + injection candidate, ASC30
Severe Weakness, One-Sided Numbness, Or New Vision/Speech Changes Even outside of classic stroke presentations, urgent evaluation is warranted when numbness and tingling are paired with: New or severe weakness Rapidly worsening symptoms One-sided numbness involving the face, arm, or leg New difficulty speaking, swallowing, or seeing New loss of balance or severe headache with neurologic symptoms These combinations point to nervous system involvement beyond a mild peripheral nerve irritation
This makes the medication a dual antagonist for these receptors, offering patients successful weight loss via appetite suppression and increased feelings of satiety from smaller portions of food
